The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
NATERA, INC. COM 632307104   3,577,764 64,441 SH   SOLE   0 0 64,441
UNITY BIOTECHNOLOGY, INC. COM 91381U200   1,637,852 1,004,817 SH   SOLE   0 0 1,004,817
DENALI THERAPEUTICS, INC. COM 24823R105   59,183,977 2,568,749 SH   SOLE   0 0 2,568,749
KARUNA THERAPEUTICS, INC. COM 48576A100   5,449,200 30,000 SH   SOLE   0 0 30,000
SINGULAR GENOMICS SYSTEMS, INC. COM 82933R100   4,596,700 3,798,926 SH   SOLE   0 0 3,798,926
EQRX, INC. COM 26886C107   70,490,628 36,335,375 SH   SOLE   0 0 36,335,375
ERASCA, INC. COM 29479A108   33,277,218 11,055,554 SH   SOLE   0 0 11,055,554
VERVE THERAPEUTICS, INC. COM 92539P101   28,967,026 2,008,809 SH   SOLE   0 0 2,008,809